ZetaGen Therapeutics key facts
as of Oct 2026- Developer of a small molecule-based osteoinductive technology designed to suspend cancer, inhibit pain and regenerate bone.
- ZetaGen Therapeutics is valued at approximately $180.0M as of Oct 2026, set at its later-stage round, Jan 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $52.5M across 4 recorded rounds; the latest was Early Stage VC ($12.9M) in Jan 2025.
- Notable investors include National Institutes of Health, New York Ventures, AJU IB Investment, JStar Capital, National Institutes of Arthritis and Musculoskeletal Diseases.
- ZetaGen Therapeutics has filed 5 Form Ds with the SEC since 2018, most recently Nov 2025 ($12.9M sold to 35 investors).
- Status: Privately Held (backing).
Valued at $180.0M at its later-stage round, Jan 2025. Nothing has traded since.
- ·Watch ZetaGen Therapeutics: the Monday email on marks, rounds and moves
ZetaGen Therapeutics funding rounds
4 roundsZetaGen Therapeutics valuation
ZetaGen Therapeutics was valued at $180 million at its later-stage round in Jan 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has ZetaGen Therapeutics raised?
ZetaGen Therapeutics has raised $52.5 million in total; 4 of its rounds are on record, from 2018 on. The largest on record was a $9.6 million early-stage round in Apr 2022; the most recent was a $12.9 million early-stage round in Jan 2025.
ZetaGen Therapeutics has filed 5 Form Ds with the SEC since 2018, most recently in Nov 2025 ($12.9 million sold to 35 investors).
ZetaGen Therapeutics investors
5 investors are on record for ZetaGen Therapeutics, including National Institutes of Health, New York Ventures, AJU IB Investment and JStar Capital. The early-stage round in Jan 2025 drew 35 investors.
About ZetaGen Therapeutics
Developer of a small molecule-based osteoinductive technology designed to suspend cancer, inhibit pain and regenerate bone. The company's technology can transform the treatment of bone-related injuries, procedures and diseases, suspend cancer growth, alleviate pain and promote bone regeneration, enabling healthcare professionals to encompass several oncological candidates targeting metastatic and primary cancers for breast, lung, prostate and bone sarcomas.
- Sector
- Healthcare
- HQ
- Syracuse, NY, United States
- Founded
- 2015
- Employees
- 9
- Website
- zetagen.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.